Selecting & Optimizing State-of-the-Art, Predictive, & Cost-Effective Models to Enhance Target Selection, Facilitate Biomarker Discovery & Achieve Clinical Translatability
Thank You to Our Speakers, Sponsors, and Delegates Who Joined Us in 2025! If You Are Interested in the 2026 Summit, Please Get in Touch at: info@hansonwade.com
Welcome to Tumour Models Summit Nordics
The First Summit Dedicated to Networking & Discussing New Trends in Tumour Models in the Nordics
The inherent heterogeneity of cancer - both inter-patient and intra-tumoral – remains a significant challenge in cancer modelling. With only 5% of cancer drugs successfully advancing to clinical trials, there is a critical need for more accurate and predictive models to guide therapeutic development.
For the first time ever, the Tumour Models Summit Nordics united pharma, biotech, and research leaders across the thriving Nordic biotech ecosystem to tackle this challenge head-on. As the region’s only industry-led event of its kind, this summit provided attendees with a rare opportunity to connect with top experts in preclinical and translational research.
Attendees gained leading insights into the cutting-edge innovation in in vivo and in vitro tumour modelling, discovering strategies to de-risk their studies, whilst learning how to refine their drug development pipelines. Register your interest to be kept up to date on the 2026 meeting where you will be able to engage with decision-makers, explore ground breaking solutions, and accelerate the path from lab to patient in the rapidly evolving oncology landscape.
Who Attended in 2025?
What Did Attendees Join Us for in 2025?
This summit offered a focused exploration of the most critical topics in tumour modelling through dynamic discussion, actional case studies, and expert insights. Key highlights included:

Leveraging Cutting-Edge 3D in vitro models with Roche: Understanding how 3D infiltration platforms can effectively evaluate immunotherapy modes of action and explore comparisons to in vivo

Target/Receptor Axis Modelling with Anocca: Exploring engineered T-cells for systematic determination of target/receptor activity

Humanised Mouse Models with BioInvent: Investigating the potential of single and double humanised mouse models for bispecific development

Advanced Omics Data with Curacell: Unlocking mechanisms of action using cell sequencing technologies to refine therapeutic protocols

Treating Solid Tumours with Hemispherian: Discovering innovative DNA-targeting mechanisms to selectively kill cancer cells
2025 Speakers Included

Reagan Jarvis
Chief Executive Officer
Anocca

Robin Löving
Chief Scientific Officer
Salipro Biotech

Lucas Arruda
Chief Scientific Officer
CuraCell

Jette Lange
Director of Non-Clinical Department
ADCendo

Santiago Parpal
Principal Scientist
Sprint Bioscience

Linda Mårtensson
Senior Research Scientist
BioInvent
What Past Attendees Had to Say About the Tumour Models Series
"This summit included the most cutting-edge achievements and potential collaborations in the scientific and industrial world”
Roche
“Cutting edge presentations on innovations in translational biology of several cancers and opportunities to have independent discussions with CROs”
Aperion Therapeutics
“It is such a pleasure to meet experts in the field of IO tumour models. This is a tricky field and sharing the challenges we are experiencing accelerates development of these paradigm-changing therapies”
Astellas
“The programme of presentations was rich and varied. Presentation time was also good (not too short or too long). The size of the event was favourable for networking”
Johnson & Johnson
“The conference exceeded my expectations. The talks were very relevant to my day-to-day work as in vivo scientist in a cell therapy company. I enjoyed the networking; attendees were very approachable”
Arsenal Biosciences